Newsroom

Rasterelektronenmikroskopische Aufnahme von Mycobacterium tuberculosis

News

New medicines for treating tuberculosis, malaria and other infectious diseases are still urgently needed, particularly in developing countries. The spread of antibiotic-resistant germs also results in a critical shortage of effective medications for treating and containing infectious diseases. Although this is a global problem, developing and emerging countries are particularly affected. In order to counteract this trend, researchers at the Helmholtz Centre for Infection Research (HZI) in Braunschweig and its Saarbrücken-based branch, the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), are now collaborating with Evotec, a leading drug discovery and development company, in a targeted search for new, effective drugs for treating tuberculosis (TB) and malaria. The Bill & Melinda Gates Foundation is funding this collaboration over three years with 2.3 million euros.

09.12.2019

HZI Campus

HIPS

News

The Scientific Director of the Helmholtz Centre for Infection Research (HZI), Prof Dirk Heinz, the President of Saarland University, Prof Manfred Schmitt, the Managing Director of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS, a site of HZI), Prof Rolf Müller, and the Scientific Director of the Leibniz Institute for New Materials (INM), Prof Aránzazu del Campo, signed the collaboration agreement to launch the Pharmaceutical Research Alliance Saarland today.

29.11.2019

HZI Campus

HIPS

News

Professor Rolf Müller ist mit der Ehrendoktorwürde der Shandong University in China ausgezeichnet worden. Die chinesische Partneruniversität würdigte damit die herausragenden Leistungen von Rolf Müller in der wissenschaftlichen Forschung, der internationalen Zusammenarbeit und der Talentförderung. Im Rahmen der bestehenden deutsch-chinesischen Kooperation soll die Erforschung dringend benötigter Antiinfektiva vorangebracht werden. Darüber hinaus ist Rolf Müller auf eine „Honorary Professorship“ der Universität Kapstadt berufen worden. Der Saarbrücker Forscher ist geschäftsführender Direktor des Helmholtz-Instituts für Pharmazeutische Forschung Saarland (HIPS), einer Einrichtung des Helmholtz-Zentrums für Infektionsforschung (HZI) in Kooperation mit der Universität des Saarlandes, und leitet dort die Abteilung „Mikrobielle Naturstoffe“.

27.11.2019

HIPS

News

Their ideas fight complicated urinary tract infections, ensure sustainable natural resource exploration and supply, and answer previously unanswered questions concerning nephrology and gynecology: Three Helmholtz research projects are about to bring their findings to market. To help them do so, they will receive valuable support from the largest German research organization’s “Helmholtz Enterprise” funding program.

27.11.2019

HZI Campus

Story

We live our everyday lives together with countless microbes and viruses that could also infect us. The immune system prevents many attacks, but it needs our cooperation: Proper hygiene and regular vaccinations effectively protect against infections

22.11.2019

HZI Campus

Illustration des Aufbaus eines Klasse II CRISPR-Systems

News

The CRISPR-Cas technology can be used to precisely edit DNA. Originally, it is a viral defense mechanism of bacteria. The CRISPR-Cas systems currently in use in biotechnology are classified as class II. They are characterized by a single Cas (CRISPR-associated) protein that is sufficient for the activity of the system. In contrast, class I CRISPR-Cas systems require the interaction of multiple proteins. Researchers from Duke University (USA), North Carolina State University (USA), and the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg have, for the first time, used class I-systems to regulate gene expression in human cells. The HIRI is a joint institution of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Julius Maximilian University of Würzburg. The study considerably expands the number of biotechnologically usable CRISPR-Cas systems for human therapeutics. It was published in the journal Nature Biotechnology.

22.11.2019

HIRI

Back to the first page
...
65
66
67
68
...
147

HZI in the media

... ” Seit Mai 2025 im Humanprogramm des Helmholtz-Zentrums für Infektionsforschung (HZI), Dr. Max Kellner-Leiter der jungen ...

25.09.2025

Die heutigen Nachrichten

” (Vico) within the Human program at the Helmholtz Centre for Infection Research (HZI).the‌ Vico group continues to investigate resilience

25.09.2025

World Today News

Forschende des Helmholtz-Instituts für RNA-basierte Infektionsforschung (HIRI), einem Standort des Braunschweiger Helmholtz-Zentrums für ...

19.09.2025

Verband Deutscher Biologen e.V.

purposes.

Researchers at the HIRI, a site of the Braunschweig Helmholtz Center for Infection Research (HZI), in cooperation with the Julius

19.09.2025

NewsBreak

... ihr Team vom Helmholtz-Institut für One Health (HIOH) in Greifswald – einem Standort des Helmholtz-Zentrums ...

18.09.2025

Management & Krankenhaus

... der TU Braunschweig, dem Braunschweig Integrated Centre of Systems Biology (BRICS) und dem Helmholtz-Zentrum für ...

15.09.2025

DeutschesGesundheitsPortal

Das Institut ist ein Teil des rennommierten Helmholtz-Zentrums für Infektionsforschung ...

11.09.2025

NDR Norddeutscher Rundfunk

... gearbeitet werden soll. Greifswald (dpa/mv) - In einem eigenen Gebäude sollen Forscher des Helmholtz-Instituts ...

11.09.2025

n-tv

Direktor des Helmholtz-Instituts für RNA-basierte Infektionsforschung (HIRI) in Würzburg, einem Standort des Braunschweiger Helmholtz- ...

11.09.2025

MTA Dialog

Studie und Hersteller des Prüfpräparats. Das Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS) war bei ...

11.09.2025

Kölner News Journal

at the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Institute of Molecular Infection Biology (IMIB) in Würzburg has

10.09.2025

Phys.org

Leiter der Abteilung Chemische Biologie am Helmholtz-Zentrum für Infektionsforschung in Braunschweig www.helmholtz-hzi.de ...

10.09.2025

BR Bayerischer Rundfunk

Register now for the HZI-Newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.